多模态成像市场：现况分析与预测（2023-2030）

Multimodal Imaging Market: Current Analysis and Forecast (2023-2030)

出版日期: 2023年08月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 158 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

由于製药公司加大了对多模态成像先驱的投资，因此预计多模态成像市场在预测期内将以 5% 的复合年增长率强劲增长。製药公司采用策略联盟来维持在全球市场的竞争力。同样，瑞士医疗软体公司 SOPHiA GENETICS 与製药公司阿斯特捷利康 (AstraZeneca) 合作，在癌症药物开发中利用多模态成像技术。另外，生技公司也在努力寻找使用多模态影像诊断癌症的更好方法。例如，医疗技术巨头西门子医疗将在2022年推出具有最少晶体元素的BiographVision，它将提供更高的空间分辨率，改变癌症诊断中病灶的可检测性。医疗保健领域的大规模投资预计将使多模态成像市场的机会多样化并呈指数级扩大。

依技术划分，市场分为 PET/CT、SPECT/CT、PET/MR、OCT/眼底影像等。由于能够检测体内异常活动，PET/CT 在 2022 年占据了最高的市场。 PET/CT 已被发现比其他诊断影像测试更灵敏、更准确。最近的发展已将人工智慧 (AI) 整合到 PET/CT 中，以提高影像品质并优化日常工作流程。同样，联影于 2023 年 7 月在核医学和分子影像学会 (SNMMI) 上宣布推出具有下一代 PET/CT 系统和无缝 AI 的整合分子技术平台。因此，技术先进产品的快速推出正在推动该细分市场在预测期内的成长。

根据应用，市场分为肿瘤学、心臟科、神经学、骨科等。由于癌症患者的增加，2022年的市场份额由癌症领域主导。美国癌症协会估计，到 2023 年，美国将新增超过 190 万癌症病例，约 60 万人死于癌症。另外，这是由于寻找癌症永久治疗方法的研究和开发工作不断增加，以及由于其靶向性质而更多地采用诊断扫描仪对转移性肿瘤细胞进行成像，这对该领域的增长产生了积极影响。例如，2023年2月，美国 FDA 核准 Gemperi 用于治疗错配修復缺陷（dMMR）、復发或晚期子宫内膜癌的成年患者。因此，癌症盛行率的增加正在推动癌症领域的发展。

依最终用户划分，市场分为医院、诊断影像中心等。由于近年来政府支持力道加大，医院类别在2022年占据市场份额最高。例如，2021 年 8 月，韩国政府资助了由韩国国家研究基金会 (NRF) 领导的一个项目，研究利用多模态成像可视化骨转移中肿瘤微环境的可行性。预计此类举措将对细分市场的成长产生正面影响。因此，越来越多的政府措施正在推动医院的发展。

为了更了解多模态影像产业的市场采用情况，将市场分为北美（美国、加拿大和北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利和欧洲其他地区） ,亚太地区根据全球分布（中国、日本、印度、亚太地区其他地区）和世界其他国家进行分析。 2022年的市场由北美主导。有几个因素正在推动该区域市场的发展，包括医疗保健支出的增加、慢性病的快速增加、患者意识的提高、大多数主要参与者的存在以及随之而来的研发活动的增加。例如，美国亚马逊于 2023 年 8 月推出了一项符合 HIPAA 要求的新服务 AWS HealthImaging。它具有多模态分析功能，结合临床影像、组学数据和健康记录，为精准医疗提供医学见解。因此，医疗保健投资的增加正在推动北美多模式成像的成长。

Multimodal imaging, also known as multiplexed imaging is the incorporation of multiple imaging techniques within a single setting. This technique helps in obtaining precise characterization of body parts by making accurate differential diagnoses. Multimodal imaging combines morphofunctional information by asynchronous or synchronous means. It can help in tracking cellular events and their progression in real time in rare diseases like familial esophageal neoplasia. These are utilized for the diagnosis and management of several chronic diseases, including cancer, heart diseases, neural diseases, and others. The main advantage of multimodal imaging is the earlier detection of disease and also in localizing the cells like malignant cells of cancer. The multimodal imaging market is growing at a tremendous rate owing to a surge in the prevalence of diseases like cancer, a rise in the geriatric population, increased expenditure in healthcare, advancements in healthcare technologies, and the popularity of personalized medicine.

The Multimodal Imaging Market is expected to grow at a strong CAGR of 5% during the forecast period owing to the rising pharmaceutical investment for the development of multimodal imaging. Pharmaceutical companies have adopted strategic alliances to maintain a competitive edge in the global market. Likewise, Switzerland-based medicine software company SOPHiA GENETICS collaborated with pharmaceutical company AstraZeneca to use multimodal imaging techniques for cancer drug development. Apart from this, biotechnology companies are also making efforts to find better diagnosis methods for cancer using multimodal imaging. For instance, Medtech giant Siemens Healthineers introduced a PET/CT system with a biograph vision with minimized crystal elements, delivering a higher spatial resolution that modifies lesion detectability in cancer diagnosis in the year 2022. These bulky investments in the healthcare sector are going to diversify and amplify the opportunities tremendously in the multimodal imaging market.

Based on technology, the market is segmented into PET/CT, SPECT/CT, PET/MR, OCT/fundus imaging, and others. The PET/CT held the highest share in the market in the year 2022 owing to its ability to find abnormal activities in the body. PET/CT is found to be more sensitive and accurate than other diagnostic imaging tests. Recent developments have integrated Artificial Intelligence (AI) with PET/CT which has optimized daily workflow along with providing improved quality images. Likewise, United Imaging has introduced Next-Generation PET/CT systems and an integrated molecular technology platform with seamless AI at The Society of Nuclear Medicine and Molecular Imaging (SNMMI) in July 2023. Thus, the rapid launch of technologically advanced products is driving the growth of the segment in the forecast period.

Based on application, the market is categorized into oncology, cardiology, neurology, orthopedics, and others. The oncology segment held the dominant share in the market in 2022 owing to the rise in the prevalence of cancer cases. The American Cancer Society estimated more than 1.9 million new cancer cases and approximately 0.6 million cancer deaths in the U.S. in the year 2023. Apart from this, rising research and development for finding a permanent cure for cancer and increasing adoption of diagnostic scanners for imaging metastatic tumor cells due to their targeted nature are also having a positive impact on the growth of the segment. For instance, in February 2023, the U.S. FDA granted approval to Jemperli for adult patients with mismatch repair-deficient (dMMR), and recurrent or advanced endometrial cancer. Thus, the rising prevalence of cancer is driving the growth of the oncology segment.

On the basis of end users, the market is segmented into hospitals, diagnostic imaging centers, and others. The hospital category held the highest share in the market in 2022 attributed to the rising government support in recent years. For instance, the Korean government funded a project on potential visualization of tumor microenvironment in bone metastasis using multimodal imaging in August 2021 led by the National Research Foundation of Korea (NRF). Such initiatives are expected to positively affect the segment growth. Thus, the rising government initiatives are driving the growth of the hospital.

For a better understanding of the market adoption of the multimodal imaging industry, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the market in 2022. Several factors such as increasing healthcare expenditure, the surge in the prevalence of chronic diseases, rising patient awareness, and the presence of the majority of key players and their associated surge in research and development activities are driving the regional market. For instance, in August 2023, U.S's Amazon launched its new HIPAA-eligible service- AWS HealthImaging which is equipped with a multimodal analysis feature that combines clinical imaging with omics data as well as health records to provide medical insights for precision medicine. Hence, the rising investments in healthcare are driving the growth of multimodal imaging in North America.

Some of the major players operating in the market include: Siemens; Bruker; GE Healthcare; Canon Inc.; Mediso Ltd.; MILabs B.V.; MR Solutions Ltd.; Koninklijke Philips N.V.; PerkinElmer, Inc.; Shanghai United Imaging Healthcare Co., Ltd.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Multimodal Imaging Market
2.2. Research Methodology of the Multimodal Imaging Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE MULTIMODAL IMAGING MARKET

6 MULTIMODAL IMAGING MARKET REVENUE (USD BN), 2022-2030F

7 MARKET INSIGHTS BY TECHNOLOGY

7.1. PET/CT
7.2. SPECT/CT
7.3. PET/MR
7.4. OCT/Fundus Imaging
7.5. Others

8 MARKET INSIGHTS BY APPLICATION

8.1. Oncology
8.2. Cardiology
8.3. Neurology
8.4. Orthopedics
8.5. Others

9 MARKET INSIGHTS BY END USER

9.1. Hospital
9.2. Diagnostic Imaging Centers
9.3. Others

10 MARKET INSIGHTS BY REGION

10.1. North America
- 10.1.1. U.S.
- 10.1.2. Canada
- 10.1.3. Rest of North America
10.2. Europe
- 10.2.1. Germany
- 10.2.2. U.K.
- 10.2.3. France
- 10.2.4. Italy
- 10.2.5. Spain
- 10.2.6. Rest of Europe
10.3. Asia-Pacific
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Rest of Asia-Pacific
10.4. Rest of World